| Title |
Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, March 2012
|
| DOI | 10.2147/ndt.s20683 |
| Pubmed ID | |
| Authors |
Mandeep Singh, Thomas L Schwartz |
| Abstract |
Vilazodone is the latest approved antidepressant available in the United States. Its dual mechanism of action combines the inhibition of serotonin transporters while simultaneously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in serotonin facilitation across the brain's serotonergic pathways, which has been termed by the authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Norway | 1 | 2% |
| South Africa | 1 | 2% |
| Unknown | 62 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 17% |
| Student > Ph. D. Student | 11 | 17% |
| Other | 6 | 9% |
| Student > Postgraduate | 5 | 8% |
| Student > Master | 5 | 8% |
| Other | 12 | 18% |
| Unknown | 16 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 24% |
| Psychology | 9 | 14% |
| Agricultural and Biological Sciences | 7 | 11% |
| Social Sciences | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Other | 7 | 11% |
| Unknown | 18 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2018.
All research outputs
#16,188,873
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,550
of 3,120 outputs
Outputs of similar age
#103,246
of 168,428 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#6
of 8 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,428 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.